JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

19.35 6.09

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.16

Max

19.62

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

15.953

84.243

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-7.55% downside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

301M

1.1B

Vorige openingsprijs

13.26

Vorige sluitingsprijs

19.35

Nieuwssentiment

By Acuity

80%

20%

328 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 feb 2026, 23:57 UTC

Marktinformatie

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 feb 2026, 23:47 UTC

Marktinformatie

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 feb 2026, 23:43 UTC

Marktinformatie

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 feb 2026, 23:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 feb 2026, 23:34 UTC

Marktinformatie

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 feb 2026, 23:26 UTC

Marktinformatie

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 feb 2026, 21:43 UTC

Marktinformatie

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 feb 2026, 21:16 UTC

Marktinformatie

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 feb 2026, 21:15 UTC

Marktinformatie

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 feb 2026, 09:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

7 feb 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 feb 2026, 05:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 feb 2026, 02:46 UTC

Acquisities, Fusies, Overnames

Big Money, High Anxiety -- Barrons.com

6 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Acquisities, Fusies, Overnames

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Marktinformatie

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Winsten

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Acquisities, Fusies, Overnames

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Winsten

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Winsten

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Marktinformatie

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Winsten

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-7.55% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -7.55%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

328 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat